September 22, 2017 10:35 AM EDT
News Briefing

Ab­b­Vie part­ners on an Op­di­vo com­bo study with Bris­tol-My­ers; In­ter­cept tum­bles on FDA warn­ing

Shehla Shakoor

Managing Director

⇨ Ab­b­Vie wants to ex­plore how a com­bi­na­tion of its an­ti-c-Met an­ti­body drug AB­BV-399 will work in com­bi­na­tion with Bris­tol-My­ers’ Op­di­vo in treat­ing non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times